相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE
Wenjia Zhu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized Candidates
Melpomeni Fani et al.
PHARMACEUTICALS (2021)
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
Valentina Ambrosini et al.
EUROPEAN JOURNAL OF CANCER (2021)
A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
Wenjia Zhu et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [177Lu]Lu-OPS201 Compared to the Agonist [177Lu]Lu-DOTA-TATE
Rosalba Mansi et al.
PHARMACEUTICALS (2021)
SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers
Raghuvir Haridas Gaonkar et al.
PHARMACEUTICALS (2021)
EANM guideline on the validation of analytical methods for radiopharmaceuticals
Nic Gillings et al.
EJNMMI RADIOPHARMACY AND CHEMISTRY (2020)
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Thomas A. Hope et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study
Guillaume P. Nicolas et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist
Keelara Abiraj et al.
EJNMMI RESEARCH (2018)
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA
Murat Fani Bozkurt et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
Damian Wild et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
Sander M. Bison et al.
CLINICAL AND TRANSLATIONAL IMAGING (2014)
First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
Damian Wild et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
Mihaela Ginj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
[99mTc]demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours:: synthesis and preclinical results
T Maina et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2002)